Focused therapeutic areas and pipeline progress

Cancer has affected people of all ages and societies throughout human history, posing a serious threat to life. Addressing this multifaceted global health issue stands as one of the most pressing challenges and missions in modern biomedical science.

mRNA-based therapeutics in cancer treatment induce antigen expression, which triggers strong, specific immune responses. This enables the development of multiple precise and effective immuno-oncology therapies. Dedicated to immuno-oncology and driven by innovation, we strive to bring hope to cancer patients globally.

An autoimmune disease occurs when the immune system fails to distinguish self from non-self and mistakenly attacks healthy cells. Current treatments only relieve symptoms and often cause side effects, highlighting the need for safer, more effective therapies.

mRNA-based therapeutics can offer a highly controllable means to code and release targeted bispecific antibodies, enhancing safety profiles. This approach holds great potential to address critical unmet needs in autoimmune disease treatment.

For centuries, the epic of humanity’s fight against infectious diseases has been marked by wisdom, resilience and scientific progress. The outbreak of COVID-19 pandemic further accelerated advancements in vaccine technology, with mRNA vaccines emerging as novel and effective tools able to activate strong immune responses, remarkable speed and efficacy.

With the aspiration to safeguard global health, we have further developed a diverse product pipeline covering varicella zoster virus (“VZV”), respiratory syncytial virus (“RSV”) and tuberculosis (“TB”).